logo
Share SHARE
FONT-SIZE Plus   Neg

CorMedix Provides Update On CE Marking Process For Neutrolin

CorMedix Inc. (CRMD) on Thursday announced the receipt of a request for additional information and data, including six month stability data on the third and final test batch from TUV-SUD and MEB-Netherlands on the CE Mark application for Neutrolin in the EU.

Upon delivery of the requested information, the company believes that Neutrolin will enter a third and final round of review to finalize the CE Mark.

CorMedix anticipates providing such additional information and data in late third quarter or early fourth quarter of 2012.

As a result, CorMedix now expects a final review and determination regarding its CE Mark application by the end of 2012.

CorMedix said it is currently in the final stages of completing its commercialization plan and is in talks with several potential partners regarding the launch of Neutrolin in Europe.

Based on the status of such talks CorMedix continues to target a commercial launch for fourth quarter of 2012 or first quarter of 2013.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Justice Department, in the antitrust trial against the proposed Aetna- Humana Merger, argued that the merger would harm senior citizens who buy private Medicare plans. The U.S. Department of Justice stated that the merger would also harm consumers who buy plans on Affordable Care Act marketplaces, reports said. However, healthcare insurers Aetna And Humana defended their proposed merger.. Telecommunications firm Sprint has extended its Black Friday unlimited data offer for a limited time, the company said in a statement on Monday. When customers switch at least one line to Sprint and sign up for Unlimited Freedom with AutoPay, they get unlimited data, talk and text starting at just $20 per month/line for a family of five until January 31, 2018. Shares of Cerecor Inc. (CERC) plunged over 13% on Monday on disappointing top-line clinical results from its phase II clinical trial of CERC-501 for smoking cessation.
comments powered by Disqus
Follow RTT